-transparent.png){kind=logo}
Carboplatin is one of the most active agents in untreated small cell lung cancer (SCLC; 14% complete response, CR; and 61% CR + partial response, PR). The combination carboplatin/etoposide/vincristine (CEV) (phase II trial) led to an overall remission rate of 84% in patients with limited disease, with 52% CR. The median survival time with this combination was 13 months in patients with limited disease and 9.5 months in those with extensive disease. The 4-year survival rates are 26% in limited disease and 8% in extensive disease, with a plateau of the survival curve. This regimen is highly effective and exhibits low toxicity in SCLC. To evaluate the role of carboplatin in combination chemotherapy in patients with extensive SCLC, a phase III trial was performed. In this ongoing trial comparing CEV and etoposide/vincristine in SCLC patients with extensive disease, CR and overall response rates are higher in the CEV arm (CR 32 vs. 17%, CR + PR 80 vs. 60%), with statistically significant difference. In summary, chemotherapy regimens containing platinum compounds are among the most active in the treatment of SCLC. The use of the new compound carboplatin instead of cisplatin has led to similar or increased remission rates and is preferable because it has fewer side effects. Preliminary results from this ongoing, prospective, randomized phase III trial will be presented.
U Gatzemeier, and
J von Pawel, and
R Laumen, and
D K Hossfeld, and
R Neuhauss, and
M Reck, and
L Lenaz
June 1995,
Seminars in oncology,
U Gatzemeier, and
J von Pawel, and
R Laumen, and
D K Hossfeld, and
R Neuhauss, and
M Reck, and
L Lenaz
January 1992,
Oncology,
U Gatzemeier, and
J von Pawel, and
R Laumen, and
D K Hossfeld, and
R Neuhauss, and
M Reck, and
L Lenaz
December 1995,
The Tokai journal of experimental and clinical medicine,
U Gatzemeier, and
J von Pawel, and
R Laumen, and
D K Hossfeld, and
R Neuhauss, and
M Reck, and
L Lenaz
January 1990,
Cancer chemotherapy and pharmacology,
U Gatzemeier, and
J von Pawel, and
R Laumen, and
D K Hossfeld, and
R Neuhauss, and
M Reck, and
L Lenaz
May 1992,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
U Gatzemeier, and
J von Pawel, and
R Laumen, and
D K Hossfeld, and
R Neuhauss, and
M Reck, and
L Lenaz
January 1994,
Acta oncologica (Stockholm, Sweden),
U Gatzemeier, and
J von Pawel, and
R Laumen, and
D K Hossfeld, and
R Neuhauss, and
M Reck, and
L Lenaz
August 1991,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
U Gatzemeier, and
J von Pawel, and
R Laumen, and
D K Hossfeld, and
R Neuhauss, and
M Reck, and
L Lenaz
February 1995,
Seminars in oncology,
U Gatzemeier, and
J von Pawel, and
R Laumen, and
D K Hossfeld, and
R Neuhauss, and
M Reck, and
L Lenaz
September 2020,
The Lancet. Oncology,
U Gatzemeier, and
J von Pawel, and
R Laumen, and
D K Hossfeld, and
R Neuhauss, and
M Reck, and
L Lenaz
December 2020,
The Lancet. Oncology,
